Press Release.

 

FOR IMMEDIATE RELEASE

Contact: Mike Duff
(703) 647-6214
mduff@alssa.org

 

ALSSA Spring Meeting to Focus on Emerging Role of Diagnostics in Healthcare

 

Alexandria, VA (February 24, 2011) — Greg Herrema, Chairman of ALSSA, The Analytical & Life Science Systems Association, today announced that the program for ALSSA’s 2011 Spring Meeting will focus on the future of healthcare and medicine with a special emphasis on the emerging role of diagnostics and the implications and market opportunities for members of ALSSA.

Directed to presidents, GMs and senior executives, especially those in finance, sales & marketing, technology and R&D, the meeting will be held on May 1–3 in Boston, Massachusetts.

Diagnostics and especially molecular diagnostics are emerging as a truly disruptive technology and critical to the future of pharmaceuticals and to the realization of personalized medicine. By offering the potential to diagnose diseases earlier and select/confirm the most appropriate therapeutic for a given individual, molecular diagnostics are expected to help contain the cost of healthcare while improving the quality of medicine, expanding access and shifting medicine closer to the patient.

Investment firms believe the molecular diagnostics market to have long-term and sustainable growth potential, Many analysts estimate the market will grow at an annual rate of 10–15 percent.

The day-and-a-half program will feature the following speakers:

  • Martin Madaus, formerly President & CEO of Millipore Corporation and Roche Diagnostics, will present a strategic overview and assessment of the diagnostics business and discuss the opportunities and pitfalls for companies developing business in that space.
  • Peter Lawson, Executive Director of Equity Research and Healthcare Analyst, with Mizuho Securities USA will present a Wall Street perspective on the outlook for diagnostics and the factors that will influence future growth in that market.
  • Michael Little, Global Head of Diagnostics Development at Novartis, will share his views on how pharmaceutical companies will use molecular diagnostics, and help drive the development of new diagnostics technologies.
  • Steve Little, Vice President of Personalized Healthcare at QIAGEN, will complement the Novartis presentation with a supplier’s perspective on the prospects for companion diagnostics.
  • Rob Epstein, Chief Technology Officer of Medco, will explain how Medco is using molecular diagnostics, where they see the field heading and the practical challenges.
  • Professor Ranjay Gulati of the Harvard Business School, a highly regarded academic, will outline a strategy for business growth based on putting customers at the center of your business.
  • Patrick Sluss of Harvard Medical School and Mass General Hospital will present a clinical perspective and discuss future clinical needs and drivers.

 

 

For more information regarding ALSSA’s Board of Directors contact Mike Duff, President of ALSSA, at 703-647-6214. More information regarding ALSSA can be found at www.alssa.org.

ALSSA is the primary trade association for companies that develop and market technologies and solutions that enable scientific discoveries worldwide and applications which benefit society and lead to advances in healthcare, industrial innovation, and a safe and clean environment.

ALSSA members provide the “tools” and “solutions” essential to conduct research, testing, discovery and product development in a wide range of industries and applications including:

 

  • Pharmaceuticals and Drug Discovery
  • University and Scientific Research
  • Biotechnology
  • Forensics
  • Chemicals and Chemical Processing
  • Molecular Diagnostics Testing
  • Food Safety
  • Environmental Testing
  • Medical and Life Science Research

     

    # # #
    Press

    Join ALSSA Today - Click here for more information.

    “ALSSA meetings and events provide me with the opportunity to develop and strengthen key relationships with senior industry executives and to also connect with emerging and start up companies in our industry.”

    Jay Flatley
    President & CEO
    Illumina, Inc.